Short Interest in Pharma Mar (OTCMKTS:PHMMF) Declines By 94.8%

Pharma Mar (OTCMKTS:PHMMF) was the recipient of a significant decline in short interest in July. As of July 15th, there was short interest totaling 13 shares, a decline of 94.8% from the June 30th total of 252 shares. Based on an average daily trading volume, of 93 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are short sold.

Analyst Ratings Changes

PHMMF has been the subject of a number of recent research reports. BTIG Research initiated coverage on shares of Pharma Mar in a research note on Thursday, April 23rd. They issued a “buy” rating for the company. Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. Finally, Zacks Research raised shares of Pharma Mar to a “hold” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Pharma Mar presently has an average rating of “Buy”.

Pharma Mar Price Performance

Shares of Pharma Mar stock remained flat at $86.09 during midday trading on Friday. The company had a trading volume of 41 shares, compared to its average volume of 23. The firm has a 50 day simple moving average of $91.98 and a 200 day simple moving average of $93.84. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. Pharma Mar has a 1-year low of $77.41 and a 1-year high of $110.40.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.